Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Pipeline Review, H2 2018

Publisher Name :
Date: 10-Jul-2018
No. of pages: 54

Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Pipeline Review, H2 2018

Summary

According to the recently published report 'Macrophage Stimulating Protein Receptor - Pipeline Review, H2 2018'; Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) pipeline Target constitutes close to 6 molecules.

Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Macrophage-stimulating protein receptor is a protein encoded by the MST1R gene. It regulates many physiological processes including cell survival, migration and differentiation. Upon ligand binding at the cell surface it induces autophosphorylation of RON on its intracellular domain that provides docking sites for downstream signaling molecules and interacts with the PI3-kinase subunit PIK3R1, PLCG1.

The report 'Macrophage Stimulating Protein Receptor - Pipeline Review, H2 2018' outlays comprehensive information on the Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 2 and 1 respectively.

Report covers products from therapy areas Oncology and Metabolic Disorders which include indications Gastric Cancer, Breast Cancer, Anaplastic Large Cell Lymphoma (ALCL), Anaplastic Thyroid Cancer, Bile Duct Cancer (Cholangiocarcinoma), Clear Cell Squamous Cell Carcinoma, Colon Cancer, Colorectal Cancer, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Lung Cancer, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Ovarian Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Multiple Myeloma (Kahler Disease), Neuroblastoma, Osteoporosis, Pancreatic Cancer, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma, Rhabdomyosarcoma and Uveal Melanoma.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1)

- The report reviews Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects

- The report assesses Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Pipeline Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Overview
Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Companies Involved in Therapeutics Development
Advenchen Laboratories LLC
Aslan Pharmaceuticals Pte Ltd
Bristol-Myers Squibb Co
Lead Discovery Center GmbH
Pfizer Inc
SignalChem Lifesciences Corp
Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Drug Profiles
AL-2846 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASLAN-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-777607 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
crizotinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize RON Kinase for Pancreatic Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit MST1R for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Dormant Products
Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Discontinued Products
Macrophage Stimulating Protein Receptor (CDw136 or Protein Tyrosine Kinase 8 or p185 Ron or CD136 or MST1R or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
Jun 11, 2018: Pfizer's Xalkori accepted for use in NHS Scotland
Jun 02, 2018: Updated Phase 1 results of crizotinib against MET-amplified non-small cell lung cancer
May 29, 2018: Pfizer's XALKORI (crizotinib) Receives FDA Breakthrough Therapy Designation in Two New Indications
Apr 15, 2018: Crizotinib Yielded a High Objective Response Rate for Adult Patients With ALK-positive Inflammatory Myofibroblastic Tumor
Apr 02, 2018: Lung cancer drug shows promise as targeted therapy for thousands with breast cancer
Feb 05, 2018: Adding crizotinib to radiation therapy may help preserve hearing in patients with NF2
Dec 08, 2017: Largest trial ever performed in alveolar soft part sarcoma: results published
Nov 14, 2017: XALKORI Approved by Health Canada for the Treatment of Patients with ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Sep 20, 2017: Publication of EORTC 90101 "CREATE" Phase II trial
Sep 11, 2017: Pfizer Presents Overall Survival Data of XALKORI in Patients With ALK-positive Advanced Non-small Cell Lung Cancer
Aug 30, 2017: New approach to genetic testing matches lung cancer patient with life-saving drug
Jun 02, 2017: OxOnc Announces that Co-development Partner Has Received Approval in Japan and Taiwan for Crizotinib (Xalkori) as a First-line Treatment for Patients with ROS1-Positive Non-Small Cell Lung Cancer
Feb 15, 2017: ASLAN Pharmaceuticals' new ASLAN002 (BMS777607) phase 1 data published in Science Translational Medicine
Feb 03, 2017: AmoyDx ROS1 Fusion Test Kit was Approved by Japanese Authority as Companion Diagnostics for Pfizers Crizotinib
Jan 05, 2017: HTG Molecular Diagnostics Completes Module Three Filing for HTG EdgeSeq ALKPlus Assay PMA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Advenchen Laboratories LLC, H2 2018
Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2018
Pipeline by Bristol-Myers Squibb Co, H2 2018
Pipeline by Lead Discovery Center GmbH, H2 2018
Pipeline by Pfizer Inc, H2 2018
Pipeline by SignalChem Lifesciences Corp, H2 2018
Dormant Projects, H2 2018
Discontinued Products, H2 2018

List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
  • Global Effervescent Tablet Market Insights, Forecast to 2025
    Published: 13-Nov-2018        Price: US 3900 Onwards        Pages: 116
    Effervescent tablets are designed to break in contact with liquid such as water or juice, often causing the tablet to dissolve into a solution. In 2017, the global Effervescent Tablet market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from 2018. The objectives of this study are to define, segment, and project the size of the Effervescent Tablet market based on company, product type, application and key regions. This report stud......
  • Global DHA Oil Market Insights, Forecast to 2025
    Published: 13-Nov-2018        Price: US 3900 Onwards        Pages: 107
    This report studies the global market size of DHA Oil in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of DHA Oil in these regions. This research report categorizes the global DHA Oil market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges......
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Review, H2 2018
    Published: 13-Nov-2018        Price: US 2000 Onwards        Pages: 31
    End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide End-Stage Kidney Disease - Pipeline Review, H2 2018, provides an overview of the End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline landscape. End-stage kidney disease is the complete or almost complete failure of the kidneys to work. Symptoms include inabili......
  • Global Rivanol Market Insights, Forecast to 2025
    Published: 13-Nov-2018        Price: US 3900 Onwards        Pages: 117
    Rivanol is for external use sterilization preservative, the gram positive bacteria and a few gram-negative bacteria have strong exterminate action, to cocci especially streptococcus antibacterial effect strong. It is used for all kinds of wounds, seepage, erosion of infectious skin disease and wound flushing. In 2017, the global Rivanol market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from 2018. The objectives of this study are to define, ......
  • Global Omega 3-6-9 Market Insights, Forecast to 2025
    Published: 13-Nov-2018        Price: US 3900 Onwards        Pages: 104
    This report studies the global market size of Omega 3-6-9 in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Omega 3-6-9 in these regions. This research report categorizes the global Omega 3-6-9 market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities an......
  • Global Scaffold Free 3D Cell Culture Plate Market Insights, Forecast to 2025
    Published: 13-Nov-2018        Price: US 3900 Onwards        Pages: 118
    This report studies the global market size of Scaffold Free 3D Cell Culture Plate in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Scaffold Free 3D Cell Culture Plate in these regions. This research report categorizes the global Scaffold Free 3D Cell Culture Plate market by players/brands, region, type and application. This report also studies the global market status, competition landscape, ma......
  • Hypothyroidism - Pipeline Review, H2 2018
    Published: 13-Nov-2018        Price: US 2000 Onwards        Pages: 30
    Hypothyroidism - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypothyroidism - Pipeline Review, H2 2018, provides an overview of the Hypothyroidism (Hormonal Disorders) pipeline landscape. Hypothyroidism (underactive thyroid) is a condition in which thyroid gland doesn't produce enough of certain important hormones. Signs and symptom include fatigue, constipation, dry skin, puffy face, ......
  • Global Pregnant Vitamin Market Insights, Forecast to 2025
    Published: 13-Nov-2018        Price: US 3900 Onwards        Pages: 115
    For pregnant women, vitamin supplements are needed during pregnancy to ensure adequate nutrition for the fetus. Vitamins are essential not only for pregnant women, but also for the development of babies. In 2017, the global Pregnant Vitamin market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from 2018. The objectives of this study are to define, segment, and project the size of the Pregnant Vitamin market based on company, product type, applic......
  • Hypoparathyroidism - Pipeline Review, H2 2018
    Published: 13-Nov-2018        Price: US 2000 Onwards        Pages: 51
    Hypoparathyroidism - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypoparathyroidism - Pipeline Review, H2 2018, provides an overview of the Hypoparathyroidism (Hormonal Disorders) pipeline landscape. Hypoparathyroidism is decreased function of the parathyroid glands with underproduction of parathyroid hormone. This leads to low levels of calcium in the blood, often causing cramping and......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs